Tempest Therapeutics

TPST · Nasdaq · United States

Share price · TPST

$0.31-0.76 (-71.09%) 3M

close as of 2026-11-18 · 24h delayed · vol 196K (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TPST's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Sep 2026+29.2%
  2. 21 Sep 2026-20.1%
  3. 17 Sep 2026-26.0%
  4. 16 Sep 2026+60.2%
  5. 10 Sep 2026-11.7%
  6. 17 Aug 2026+11.3%

    Nothing announced by TPST that day or the session before.

  7. 14 Aug 2026-13.2%
  8. 11 Aug 2026+13.5%
  9. 10 Aug 2026+13.5%
  10. 14 May 2026+13.6%

Share of unusual movement by asset

For each asset, the share of TPST's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Amezalpat
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—53%
Sessions with no dated event—46%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
PPARα (peroxisome proliferator-activated receptor alpha)Small molecule
Hepatocellular Carcinoma

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
AmezalpatPhase 3Hepatocellular Carcinoma (HCC)
Est. primary completion 2028-12 · NCT06680258 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$0.2M$0.9M$3.6M-$2.0M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$1.8M$1.2M$5.2M-$2.8M operating cash flowreport ↗
2026-Q1—$0.1M$2.3M$28M-$7.6M operating cash flowreport ↗
2025-Q3—$0.6M$8.0M$3.5M-$6.8M operating cash flowreport ↗
2025-Q2—$3.9M$15M$7.9M-$8.4M operating cash flowreport ↗
2025-Q1—$7.6M$22M$11M-$8.0M operating cash flowreport ↗
2024-Q3—$7.6M$23M$11M-$10M operating cash flowreport ↗
2024-Q2—$5.8M$32M$9.6M-$5.5M operating cash flowreport ↗
2024-Q1—$4.3M$33M$7.9M-$7.2M operating cash flowreport ↗
2023-Q3—$4.2M$12M$6.8M-$6.5M operating cash flowreport ↗
2023-Q2—$4.4M$18M$7.6M-$6.4M operating cash flowreport ↗
2023-Q1—$4.7M$23M$7.6M-$8.3M operating cash flowreport ↗
2022-Q3—$6.0M$43M$8.9M-$9.1M operating cash flowreport ↗
2022-Q2—$5.7M$52M$9.2M-$8.4M operating cash flowreport ↗
2022-Q1—$5.1M$46M$8.5M-$7.1M operating cash flowreport ↗
2021-Q4——$52M$28M-$8.0M operating cash flowreport ↗
2021-Q3—$4.6M$60M$8.1M-$12M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$13M$7.7M$26Mreport ↗

Tempest Therapeutics reported no revenue for the full year 2025. R&D expense was $12.6M, down 55.8% YoY from $28.5M, and the company ended the year with $7.7M in cash and cash equivalents. Net loss was $26.3M, or $6.33 per share, compared to a net loss of $41.8M, or $19.50 per share, in the prior year.

The company highlighted completion of its strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience, appointment of Matt Angel, Ph.D., as CEO and President, and positive interim data from the REDEEM-1 Phase 1/2a trial of TPST-2003 in relapsed/refractory multiple myeloma, including a 100% complete response rate in six efficacy-evaluable patients. Management also noted potential 2026 milestones, including a U.S. IND submission and initiation of a Phase 2b registrational study for TPST-2003, plus a planned Phase 2 study of TPST-1495 in familial adenomatous polyposis expected to be funded by the National Cancer Institute.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$29M$30M$42Mreport ↗
2023-FY—$18M$40M$7.4M-$27M operating cash flowreport ↗
2022-FY—$23M$32M$8.9M-$31M operating cash flowreport ↗
2021-FY—$17M$52M$7.1M-$26M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($1.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-13Frederick John W. · directorAward / grant (derivative)25,000——Form 4
2026-09-22Smith Nancy Freda · directorAward / grant (derivative)25,000——Form 4
2026-06-04Yee John D. · directorAward / grant (derivative)25,000——Form 4
2026-06-04Richey William Drake · directorAward / grant (derivative)25,000——Form 4
2026-03-31Maestas Nicholas · Chief Financial OfficerAward / grant (derivative)140,000——Form 4
2026-03-31Trojanowski Justin · Corporate ControllerAward / grant (derivative)22,000——Form 4
2026-03-24Angel Matthew · director, CEO and President, 10% ownerOpen-market purchase231,482$2.16$500KForm 4
2026-03-24Angel Matthew · director, CEO and President, 10% ownerOpen-market purchase (derivative)231,482——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 21 reporting institutions held 0.5M shares ($848K, 2.6% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC233,888$384K
2GEODE CAPITAL MANAGEMENT, LLC86,990$143K
3VANGUARD FIDUCIARY TRUST CO68,908$113K
4BlackRock, Inc.39,068$64K
5FMR LLC33,225$54K
6SABBY MANAGEMENT, LLC17,856$29K
7NORTHERN TRUST CORP14,053$23K
8DIMENSIONAL FUND ADVISORS LP11,444$19K
9UBS Group AG4,533$7K
10Tower Research Capital LLC (TRC)2,790$5K
11MORGAN STANLEY2,058$3K
12OSAIC HOLDINGS, INC.1,529$2K
13Federation des caisses Desjardins du Quebec292$479
14JONES FINANCIAL COMPANIES LLLP239$413
15Vanguard Global Advisers, LLC168$276